1-[(3S,8S,9S,10R,13R,14S,17S)-3-methoxy-10,13-dimethyl-2,3,4,7,8,9,11, 12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
中文名称 | 1-[(3S,8S,9S,10R,13R,14S,17S)-3-methoxy-10,13-dimethyl-2,3,4,7,8,9,11, 12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone |
---|---|
中文同义词 | 化合物MAP4343 |
英文名称 | 1-[(3S,8S,9S,10R,13R,14S,17S)-3-methoxy-10,13-dimethyl-2,3,4,7,8,9,11, 12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone |
英文同义词 | 1-[(3S,8S,9S,10R,13R,14S,17S)-3-methoxy-10,13-dimethyl-2,3,4,7,8,9,11, 12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone;MAP4343;Pregn-5-en-20-one, 3-methoxy-, (3β)-;5-Pregnen-3B-ol-20-one-17a,21,21,21-d4 3-Methyl Ether;inhibit,microtubule-associated,Microtubule/Tubulin,Pregnenolone,MAP2,tubulin,polymerization,neurites,MAP 4343,MAP4343,Inhibitor,MAP-4343,protein |
CAS号 | 511-26-2 |
分子式 | C22H34O2 |
分子量 | 330.5 |
EINECS号 | |
相关类别 | |
Mol文件 | 511-26-2.mol |
结构式 |
1-[(3S,8S,9S,10R,13R,14S,17S)-3-methoxy-10,13-dimethyl-2,3,4,7,8,9,11, 12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone 性质
熔点 | 123.5° |
---|---|
比旋光度 | D18 +18° (c = 1.085 in chloroform) |
沸点 | 426.6±45.0 °C(Predicted) |
密度 | 1.04±0.1 g/cm3(Predicted) |
储存条件 | Store at -20°C |
溶解度 | 二甲基亚砜:25 mg/mL(75.64 mM) |
形态 | 固体 |
颜色 | 白色至米白色 |
1-[(3S,8S,9S,10R,13R,14S,17S)-3-methoxy-10,13-dimethyl-2,3,4,7,8,9,11, 12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone 用途与合成方法
MAP4343 (40 μM; 15 or 30 min) stimulates microtubule polymerization in vitro.
MAP4343 (30 μM; 2-8 d) stimulates nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells.
MAP4343 (20 μM; 1 h) protects against microtubule depolymerization induced by Nocodazole in PC12 cells
MAP4343 (12 mg/kg; daily s.c. for 28 d) improves the recovery of locomotor function after spinal cord injury (SCI) in rats.
MAP4343 (4 mg/kg; daily s.c. for 6 d) increases MAP2 levels in spinal cord after SCI in rats.
MAP4343 (4 mg/kg; daily s.c. for 6 d) increases the size of lumbar spinal motoneurons' dendrite arbours after SCI in rats.
Animal Model: | Adult Sprague-Dawley male rats with spinal cord injury |
Dosage: | 12 mg/kg |
Administration: | Daily s.c. for 28 days |
Result: |
Increased the number of animals able to walk with weight-supported plantar steps.
Showed forelimb-hindlimb coordination at the end of the study. |
安全信息
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/08/19 | HY-107116 | 1-[(3S,8S,9S,10R,13R,14S,17S)-3-methoxy-10,13-dimethyl-2,3,4,7,8,9,11, 12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone MAP4343 | 511-26-2 | 5mg | 1000元 |
2024/08/19 | HY-107116 | 1-[(3S,8S,9S,10R,13R,14S,17S)-3-methoxy-10,13-dimethyl-2,3,4,7,8,9,11, 12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone MAP4343 | 511-26-2 | 10mM * 1mLin DMSO | 1100元 |